Cytokine-induced killer (CIK) cells, successes and challenges: report on the first international conference dedicated to the clinical translation of this unique adoptive cell immunotherapy-Reference-Cited by-同舟云学术

Cytokine-induced killer (CIK) cells, successes and challenges: report on the first international conference dedicated to the clinical translation of this unique adoptive cell immunotherapy

Published:2024-01-27 Issue:2 Volume:73 Page:
ISSN:1432-0851
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Sharma Amit,Ren Xiubao,Rosato Antonio,Sangiolo Dario,Wang Zibing,Tettamanti Sarah,Zhang Yi,Rettinger Eva,Fenix Kevin Aaron,Sommaggio Roberta,Cappuzzello Elisa,Schmidt-Wolf Ingo G. H.

Abstract

AbstractOn August 30, 2023, experts from Germany and abroad met to discuss the successes and challenges of cytokine-induced killer cell (CIK) therapy, that recently celebrated its 30th anniversary providing treatment for cancer. This first virtual conference was hosted by CIO Bonn, a certified Comprehensive Cancer Center (CCC) funded by German Cancer Aid (DKH). In addition to keynote speakers involved in CIK cell clinical trials or optimized preclinical models to improve this adoptive cell immunotherapy, more than 100 attendees from around the world also participated in this event. Initiatives to establish the International Society of CIK Cells (ISCC) and a stronger CIK cell network guiding preclinical research and future clinical trials were also announced.

Funder

Universitätsklinikum Bonn

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00262-023-03605-1.pdf

Reference23 articles.

1. Sharma A, Schmidt-Wolf IGH (2021) 30 years of CIK cell therapy: recapitulating the key breakthroughs and future perspective. J Exp Clin Cancer Res 40(1):388. https://doi.org/10.1186/s13046-021-02184-2

2. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL (1991) Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174(1):139–149. https://doi.org/10.1084/jem.174.1.139

3. Schmidt-wolf IGH, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N et al (1999) Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer lymphoma. Br J Cancer 81:1009–1016. https://doi.org/10.1038/sj.bjc.6690800

4. Zhang Y, Schmidt-Wolf IGH (2020) Ten-year update of the international registry on cytokine-induced killer cells in cancer immunotherapy. J Cell Physiol 235(12):9291–9303. https://doi.org/10.1002/jcp.29827

5. Liu L, Gao Q, Jiang J et al (2020) Randomized, multicenter, open-label trial of autologous cytokine-induced killer cell immunotherapy plus chemotherapy for squamous non-small-cell lung cancer: NCT01631357. Signal Transduct Target Ther 5(1):244